View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Technology
August 24, 2009

Nanosphere Submits 510(k) Application To FDA For Verigene

For its influenza and respiratory syncytial virus test to run on the Verigene SP

By CBR Staff Writer

Nanosphere has submitted a 510(k) application to the FDA for its influenza and respiratory syncytial virus (RSV) test to run on the Verigene SP, with complete sample-to-result automation.

The company said that Verigene SP will provide automated sample-to-result molecular diagnostics capabilities in a multiplexed, random-access, modular system, utilizing the same imaging technology as the first generation Verigene.

Nanosphere plans to submit additional FDA applications for each of its previously 510(k) cleared assays to allow their use on the new Verigene SP.

William Moffitt, president and CEO of Nanosphere, said: We are pleased to reach this milestone and look forward to completing the regulatory process and bringing our respiratory assay to market on this highly differentiated platform.

Content from our partners
Unlocking growth through hybrid cloud: 5 key takeaways
How businesses can safeguard themselves on the cyber frontline
How hackers’ tactics are evolving in an increasingly complex landscape

The market has strongly signaled its need for a flu test that provides greater sensitivity than currently available rapid tests, combined with optimized ease of use and turnaround time not found in either traditional culture methods or the currently available molecular tests. Our respiratory panel running on the Verigene SP directly addresses these market needs, he added.

Websites in our network
Select and enter your corporate email address Tech Monitor's research, insight and analysis examines the frontiers of digital transformation to help tech leaders navigate the future. Our Changelog newsletter delivers our best work to your inbox every week.
  • CIO
  • CTO
  • CISO
  • CSO
  • CFO
  • CDO
  • CEO
  • Architect Founder
  • MD
  • Director
  • Manager
  • Other
Visit our privacy policy for more information about our services, how New Statesman Media Group may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
THANK YOU